| Metric | Q2'25 | Q3'25 | Change |
|---|---|---|---|
| Total Revenue | $676M (+16% YoY) | $699M (+15% YoY) | Beat guidance, growth decelerating |
| Non-GAAP Operating Income | $280M (41.4% margin) | $304M (43.5% margin) | +210 bps margin expansion |
| Commercial Revenue Growth | 11% YoY | 11% YoY (noted multiple times) | Exactly flat, no acceleration |
| Development Cloud Pipeline | Some larger deals moving right | Several large strategic partnerships progressing | Upgraded from delays to progress |
| Vault CRM Wins | 14 wins in Q2 | 13 wins in Q3 | Slight decline but still strong |
| Top 20 Pharma Vault CRM Commitments | 3 commitments | 4 commitments (Boehringer) | 33% increase in enterprise adoption |
| Services Revenue Performance | Below expectations due to delays | Beat expectations, projects accelerated | Sharp reversal from weakness to beat |
| CVMS Growth Trajectory | Predefined multi-year ramps | Proceeding as expected | No change, steady execution |
| Safety Suite Market Position | Building momentum | Approaching tipping point | Confidence upgrade without metrics |
| Crossix Performance | Strong execution | Driving commercial growth | Elevated to growth driver status |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.